Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

by Qureshi, Anila , Rutkowski, Piotr , de Pril, Veerle , Schenker, Michael , Atkins, Michael B , Gogas, Helen J , Yokota, Kenji , Dalle, Stéphane , Kim, Tae M , Butler, Marcus O , Arance, Ana M , Del Vecchio, Michele , Gonzalez, Rene , Maio, Michele , Queirolo, Paola , Larkin, James , Chiarion-Sileni, Vanna , Marquez-Rodas, Ivan , Meyer, Nicolas , Long, Georgina V , Mandala, Mario , Weber, Jeffrey , Bhatia, Shailender , Mortier, Laurent , Lebbé, Celeste , Grob, Jean-Jacques , Sabater, Javier , Smylie, Michael , Yamazaki, Naoya , Cowey, C. Lance , Atkinson, Victoria , Kudchadkar, Ragini R , Ascierto, Paolo A , Middleton, Mark R

in Adjuvants / Adjuvants, Immunologic - adverse effects / Adjuvants, Immunologic - therapeutic use / Adolescent / Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal - adverse effects / Antibodies, Monoclonal - therapeutic use / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Cancer therapies / Disease-Free Survival / Double-Blind Method / Double-blind studies / Drug dosages / FDA approval / Female / Humans / Immune checkpoint inhibitors / Immunotherapy / Intravenous administration / Ipilimumab - adverse effects / Ipilimumab - therapeutic use / Ligands / Male / Medical imaging / Melanoma / Melanoma - drug therapy / Melanoma - mortality / Melanoma - surgery / Melanoma, Cutaneous Malignant / Metastasis / Middle Aged / Monoclonal antibodies / Neoplasm Recurrence, Local / Neoplasm Staging / Nivolumab / Oncology / Quality of Life / Skin Neoplasms - drug therapy / Skin Neoplasms - mortality / Skin Neoplasms - surgery / Survival / Targeted cancer therapy / Tomography / Young Adult

2017

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

2017

Confirm

Do you wish to request the book?

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

2017

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Qureshi, Anila,

Rutkowski, Piotr,

de Pril, Veerle,

Schenker, Michael,

Atkins, Michael B,

Gogas, Helen J,

Yokota, Kenji,

Dalle, Stéphane,

Kim, Tae M,

Butler, Marcus O,

Arance, Ana M,

Del Vecchio, Michele,

Gonzalez, Rene,

Maio, Michele,

Queirolo, Paola,

Larkin, James,

Chiarion-Sileni, Vanna,

Marquez-Rodas, Ivan,

Meyer, Nicolas,

Long, Georgina V,

Mandala, Mario,

Weber, Jeffrey,

Bhatia, Shailender,

Mortier, Laurent,

Lebbé, Celeste,

Grob, Jean-Jacques,

Sabater, Javier,

Smylie, Michael,

Yamazaki, Naoya,

Cowey, C. Lance,

Atkinson, Victoria,

Kudchadkar, Ragini R,

Ascierto, Paolo A,

Middleton, Mark R

2017

Overview

In a randomized trial involving more than 900 patients undergoing resection of advanced melanoma, adjuvant nivolumab was associated with a higher rate of 12-month recurrence-free survival than ipilimumab (70.5% vs. 60.8%) and with fewer adverse events.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adjuvants

/ Adjuvants, Immunologic - adverse effects

/ Adjuvants, Immunologic - therapeutic use

/ Adolescent

/ Adult

/ Aged

/ Aged, 80 and over